ORIC PHARMACEUTICALS, INC. Sale of Stock, Consideration Received on Transaction
ORIC PHARMACEUTICALS, INC. (ORIC) had Sale of Stock, Consideration Received on Transaction of $124.40 million as of 2025-05-23, per its 10-Q filed 2026-08-03.
Financial Statements › Notes › Equity
us-gaap:SaleOfStockConsiderationReceivedOnTransaction · last filed 2026-08-03
- 2025-05-23: Sale of Stock, Consideration Received on Transaction $124.40M.
- 2024-01-22: Sale of Stock, Consideration Received on Transaction $124.80M.
- 2024-01-20: Sale of Stock, Consideration Received on Transaction $124.80M.
- 2023-06-24: Sale of Stock, Consideration Received on Transaction $84.80M.
| Period end | Sale of Stock, Consideration Received on Transaction |
|---|---|
| 2025-05-23 | $124.40M 10-Q · filed 2026-08-03 |
| 2024-01-22 | $124.80M 10-K · filed 2024-03-11 |
| 2024-01-20 | $124.80M 10-K · filed 2026-02-23 |
| 2023-06-24 | $84.80M 10-K · filed 2025-02-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |